Maria Grazia Roncarolo Explained

Maria Grazia Roncarolo
Birth Place:Turin, Italy
Alma Mater:University of Turin
Workplaces:Stanford University

Maria Grazia Roncarolo (born 17 December 1954) is an Italian pediatrician who is currently George D. Smith Professor in Stem Cell and Regenerative Medicine and Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) at Stanford University.[1] She is also the Director of the Stanford Institute of Stem Cell Biology and Regenerative Medicine along with Irving Weissman and Michael Longaker and the Director for Center for Definitive and Curative Medicine at Stanford.[2]

She was educated at the University of Turin.[1] She is a past President of the Federation of Clinical Immunology Societies,[3] and is a member of the Austrian Academy of Sciences.[4] She is an academic founder of Graphite Bio.[5] She has an h-index of 91.[6]

Awards and honors

Research career

Roncarolo is well known for identifying a peripheral subset of regulatory T cells, called type 1 regulatory T (Tr1) cells. Her team was the first to describe Tr1 cells[12] while at DNAX Research Institute of Molecular and Cellular Biology, which was later acquired by Schering-Plough and now a part of Merck. She was the principal investigator of the first clinical trial using Tr1 cells that are generated ex vivo to treat graft-versus-host disease in leukemia patients receiving a haploidentical haematopoietic stem cell transplant[13] and is the principal investigator of an additional clinical trial utilizing these cells in the United States.[14]

Roncarolo has made major contributions in the field of cell and gene therapy.  She performed fetal stem cell transplants given before birth[15] to treat inherited diseases of the immune system such as Wiskott-Aldrich Syndrome[16] She led the first stem cell-based gene therapy trial for patients with adenosine deaminase-severe combined immunodeficiency.[17] The clinical trial results led to the European Commission approval.[18] The therapy was licensed to GlaxoSmithKline and is marketed under the name Strimvelis, making it the first commercially approved ex vivo gene therapy in Europe.[19]

Notes and References

  1. Web site: Maria Grazia Roncarolo . . 23 June 2021.
  2. Web site: Stanford announces new Center for Definitive and Curative Medicine. 2022-02-08. News Center. sm.
  3. Web site: Leadership . . 4 June 2018 . 26 June 2021.
  4. Web site: Maria Grazia Roncarolo . Human Technopole . 26 June 2021.
  5. Web site: About Us: Academic Founders . Graphite Bio . 26 June 2021.
  6. Web site: Maria Grazia Roncarolo - Top Italian Scientist in Biomedical Sciences . Top Italian Scientists . 26 June 2021.
  7. Web site: Academy of Europe: ListMembersByAlphabet. 2022-02-08. www.ae-info.org.
  8. Web site: Academy of Europe: Roncarolo Maria. 2022-02-08. www.ae-info.org.
  9. Web site: Awards . 2023-09-29 . www.esgct.eu.
  10. Web site: EURORDIS - The Voice of Rare Disease Patients in Europe. 2022-02-08. www.eurordis.org.
  11. Web site: Outstanding Achievement Award ASGCT - American Society of Gene & Cell Therapy ASGCT - American Society of Gene & Cell Therapy. 2022-02-08. asgct.org.
  12. Groux. Hervé. O'Garra. Anne. Bigler. Mike. Rouleau. Matthieu. Antonenko. Svetlana. de Vries. Jan E.. Roncarolo. Maria Grazia. October 1997. A CD4 + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 389. 6652. 737–742. 10.1038/39614. 9338786. 1997Natur.389..737G. 4422991.
  13. Bacchetta. Rosa. Lucarelli. Barbarella. Sartirana. Claudia. Gregori. Silvia. Lupo Stanghellini. Maria T.. Miqueu. Patrick. Tomiuk. Stefan. Hernandez-Fuentes. Maria. Gianolini. Monica E.. Greco. Raffaella. Bernardi. Massimo. 2014. Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells. Frontiers in Immunology. 5. 16. 10.3389/fimmu.2014.00016. 1664-3224. 3907718. 24550909. free.
  14. Roncarolo. Maria Grazia. 2021-06-25. Stanford University. Use of T-allo10 Cell Infusions Combined With Mismatched Related or Mismatched Unrelated Hematopoietic Stem Cell Transplantation (HSCT) for Hematologic Malignancies.
  15. Web site: Ailing fetuses to be treated with stem cells. 2022-02-08. www.science.org. en.
  16. Aiuti. Alessandro. Biasco. Luca. Scaramuzza. Samantha. Ferrua. Francesca. Cicalese. Maria Pia. Baricordi. Cristina. Dionisio. Francesca. Calabria. Andrea. Giannelli. Stefania. Castiello. Maria Carmina. Bosticardo. Marita. 2013-08-23. Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome. Science. 341. 6148. EN. 10.1126/science.1233151. 4375961. 23845947.
  17. Aiuti. Alessandro. Cattaneo. Federica. Galimberti. Stefania. Benninghoff. Ulrike. Cassani. Barbara. Callegaro. Luciano. Scaramuzza. Samantha. Andolfi. Grazia. Mirolo. Massimiliano. Brigida. Immacolata. Tabucchi. Antonella. 2009-01-29. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. The New England Journal of Medicine. 360. 5. 447–458. 10.1056/NEJMoa0805817. 1533-4406. 19179314. free.
  18. Aiuti. Alessandro. Roncarolo. Maria Grazia. Naldini. Luigi. June 2017. Gene therapy for ADA‐SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products. EMBO Molecular Medicine. 9. 6. 737–740. 10.15252/emmm.201707573. 1757-4676. 5452047. 28396566.
  19. Web site: Gene Therapy's First Out-and-Out Cure Is Here. 2022-02-08. MIT Technology Review. en.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Maria Grazia Roncarolo".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.